|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MIER1 |
Gene summary for MIER1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MIER1 | Gene ID | 57708 |
| Gene name | MIER1 transcriptional regulator | |
| Gene Alias | ER1 | |
| Cytomap | 1p31.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q8N108 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57708 | MIER1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 9.49e-11 | -4.90e-01 | 0.0155 |
| 57708 | MIER1 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.65e-06 | 3.93e-01 | -0.1954 |
| 57708 | MIER1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.04e-02 | -3.46e-01 | 0.0338 |
| 57708 | MIER1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.83e-02 | -3.86e-01 | 0.0674 |
| 57708 | MIER1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.16e-02 | -5.19e-01 | 0.2585 |
| 57708 | MIER1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.33e-10 | -4.88e-01 | 0.3005 |
| 57708 | MIER1 | F007 | Human | Colorectum | FAP | 7.04e-05 | -4.06e-01 | 0.1176 |
| 57708 | MIER1 | A002-C-010 | Human | Colorectum | FAP | 3.37e-04 | -2.69e-01 | 0.242 |
| 57708 | MIER1 | A001-C-207 | Human | Colorectum | FAP | 9.41e-06 | -3.27e-01 | 0.1278 |
| 57708 | MIER1 | A015-C-203 | Human | Colorectum | FAP | 2.10e-20 | -4.11e-01 | -0.1294 |
| 57708 | MIER1 | A015-C-204 | Human | Colorectum | FAP | 4.77e-06 | -3.46e-01 | -0.0228 |
| 57708 | MIER1 | A014-C-040 | Human | Colorectum | FAP | 8.57e-04 | -2.79e-01 | -0.1184 |
| 57708 | MIER1 | A002-C-201 | Human | Colorectum | FAP | 5.39e-16 | -4.56e-01 | 0.0324 |
| 57708 | MIER1 | A002-C-203 | Human | Colorectum | FAP | 1.39e-06 | -3.83e-01 | 0.2786 |
| 57708 | MIER1 | A001-C-119 | Human | Colorectum | FAP | 1.87e-06 | -3.34e-01 | -0.1557 |
| 57708 | MIER1 | A001-C-108 | Human | Colorectum | FAP | 1.80e-12 | -3.91e-01 | -0.0272 |
| 57708 | MIER1 | A002-C-205 | Human | Colorectum | FAP | 2.66e-21 | -4.24e-01 | -0.1236 |
| 57708 | MIER1 | A001-C-104 | Human | Colorectum | FAP | 3.89e-03 | -3.23e-01 | 0.0184 |
| 57708 | MIER1 | A015-C-005 | Human | Colorectum | FAP | 7.45e-08 | -4.26e-01 | -0.0336 |
| 57708 | MIER1 | A015-C-006 | Human | Colorectum | FAP | 8.72e-18 | -5.51e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00987322 | Lung | IAC | macromolecule deacylation | 25/2061 | 116/18723 | 7.26e-04 | 9.60e-03 | 25 |
| GO:001657012 | Lung | AIS | histone modification | 81/1849 | 463/18723 | 2.30e-07 | 2.16e-05 | 81 |
| GO:000647611 | Lung | AIS | protein deacetylation | 23/1849 | 101/18723 | 1.06e-04 | 2.54e-03 | 23 |
| GO:00165751 | Lung | AIS | histone deacetylation | 19/1849 | 82/18723 | 3.23e-04 | 5.84e-03 | 19 |
| GO:003560111 | Lung | AIS | protein deacylation | 23/1849 | 112/18723 | 5.25e-04 | 8.42e-03 | 23 |
| GO:004312213 | Lung | AIS | regulation of I-kappaB kinase/NF-kappaB signaling | 41/1849 | 249/18723 | 7.57e-04 | 1.08e-02 | 41 |
| GO:000724913 | Lung | AIS | I-kappaB kinase/NF-kappaB signaling | 45/1849 | 281/18723 | 7.90e-04 | 1.11e-02 | 45 |
| GO:00987321 | Lung | AIS | macromolecule deacylation | 23/1849 | 116/18723 | 8.77e-04 | 1.19e-02 | 23 |
| GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
| GO:004312218 | Oral cavity | OSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 155/7305 | 249/18723 | 7.79e-14 | 4.14e-12 | 155 |
| GO:004312310 | Oral cavity | OSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 122/7305 | 186/18723 | 1.68e-13 | 8.52e-12 | 122 |
| GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
| GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
| GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
| GO:00064764 | Oral cavity | OSCC | protein deacetylation | 66/7305 | 101/18723 | 7.36e-08 | 1.30e-06 | 66 |
| GO:00165753 | Oral cavity | OSCC | histone deacetylation | 54/7305 | 82/18723 | 7.68e-07 | 1.08e-05 | 54 |
| GO:001657023 | Oral cavity | EOLP | histone modification | 98/2218 | 463/18723 | 5.58e-09 | 2.96e-07 | 98 |
| GO:004312223 | Oral cavity | EOLP | regulation of I-kappaB kinase/NF-kappaB signaling | 58/2218 | 249/18723 | 2.72e-07 | 8.22e-06 | 58 |
| GO:000724924 | Oral cavity | EOLP | I-kappaB kinase/NF-kappaB signaling | 62/2218 | 281/18723 | 8.00e-07 | 2.02e-05 | 62 |
| GO:004312322 | Oral cavity | EOLP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 42/2218 | 186/18723 | 2.54e-05 | 3.75e-04 | 42 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MIER1 | SNV | Missense_Mutation | novel | c.1414N>C | p.Val472Leu | p.V472L | Q8N108 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| MIER1 | SNV | Missense_Mutation | c.1423N>C | p.Glu475Gln | p.E475Q | Q8N108 | protein_coding | deleterious(0.05) | benign(0.03) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MIER1 | SNV | Missense_Mutation | c.328N>A | p.Asp110Asn | p.D110N | Q8N108 | protein_coding | tolerated(0.09) | benign(0.387) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MIER1 | deletion | Frame_Shift_Del | novel | c.1503delN | p.Asp502IlefsTer12 | p.D502Ifs*12 | Q8N108 | protein_coding | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD | ||
| MIER1 | insertion | Nonsense_Mutation | novel | c.160_161insAATGCACACAACACAAGGAAGTTACTGGGAATTCTTCTGTCTAGCCT | p.Val54GlufsTer15 | p.V54Efs*15 | Q8N108 | protein_coding | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| MIER1 | deletion | Frame_Shift_Del | novel | c.304delA | p.Thr102GlnfsTer7 | p.T102Qfs*7 | Q8N108 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MIER1 | SNV | Missense_Mutation | c.451N>A | p.Asp151Asn | p.D151N | Q8N108 | protein_coding | tolerated(0.47) | benign(0.25) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| MIER1 | SNV | Missense_Mutation | c.418G>A | p.Glu140Lys | p.E140K | Q8N108 | protein_coding | tolerated(0.39) | benign(0.065) | TCGA-EA-A439-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| MIER1 | SNV | Missense_Mutation | c.658G>A | p.Glu220Lys | p.E220K | Q8N108 | protein_coding | deleterious(0.04) | benign(0.277) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MIER1 | SNV | Missense_Mutation | c.138G>C | p.Arg46Ser | p.R46S | Q8N108 | protein_coding | deleterious_low_confidence(0.04) | benign(0.027) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |